Jerini AG to Wind Down its Preclinical Programs
Jerini AG has decided to end all negotiations regarding the transfer of assets associated with Jerini AG's preclinical programs and to terminate the employees associated with these programs. The decision was taken following unsuccessful efforts to find an investor for the sale of the preclinical programs. The redundancies reduce Jerini AG's head-count by more than 45.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.